These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19675543)

  • 1. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.
    Santen G; Horrigan J; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):255-62. PubMed ID: 19675543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs.
    Santen G; van Zwet E; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):248-54. PubMed ID: 19657333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting antidepressant clinical trials.
    Sussman N
    Ann Clin Psychiatry; 2007; 19(4):215-20. PubMed ID: 18058279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Justifying a "fast acting" claim for antidepressant drugs.
    Overall JE
    Psychopharmacol Bull; 1995; 31(1):45-55. PubMed ID: 7675989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors contributing to failed trials of new agents: can technology prevent some problems?
    Greist JH; Mundt JC; Kobak K
    J Clin Psychiatry; 2002; 63 Suppl 2():8-13. PubMed ID: 15453008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are two antidepressant mechanisms better than one? Issues in clinical trial design and analysis.
    Leon AC
    J Clin Psychiatry; 2004; 65 Suppl 4():31-6. PubMed ID: 15046539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling placebo response in depression trials using a longitudinal model with informative dropout.
    Gomeni R; Lavergne A; Merlo-Pich E
    Eur J Pharm Sci; 2009 Jan; 36(1):4-10. PubMed ID: 19041717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ideal trial to test differential onset of antidepressant effect.
    Leon AC; Blier P; Culpepper L; Gorman JM; Hirschfeld RM; Nierenberg AA; Roose SP; Rosenbaum JF; Stahl SM; Trivedi MH
    J Clin Psychiatry; 2001; 62 Suppl 4():34-6; discussion 37-40. PubMed ID: 11229787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
    Santen G; Danhof M; Della Pasqua O
    J Psychiatr Res; 2008 Oct; 42(14):1189-97. PubMed ID: 18353370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology.
    Leon AC
    J Clin Psychiatry; 2001; 62 Suppl 4():12-6; discussion 37-40. PubMed ID: 11229782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are 2-week trials sufficient to indicate efficacy?
    Montgomery SA
    Psychopharmacol Bull; 1995; 31(1):41-4. PubMed ID: 7675988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the placebo response in antidepressant trials.
    Rief W; Nestoriuc Y; Weiss S; Welzel E; Barsky AJ; Hofmann SG
    J Affect Disord; 2009 Nov; 118(1-3):1-8. PubMed ID: 19246102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients.
    Abbas I; Rovira J; Casanovas J; Greenfield T
    J Biomed Inform; 2008 Dec; 41(6):1053-61. PubMed ID: 18534916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs.
    Cogger KO
    J Clin Psychopharmacol; 2007 Aug; 27(4):418-20. PubMed ID: 17632240
    [No Abstract]   [Full Text] [Related]  

  • 17. Research and methodological issues for evaluating the therapeutic effectiveness of antidepressant drugs.
    Prien RF; Levine J
    Psychopharmacol Bull; 1984; 20(2):250-7. PubMed ID: 6374721
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
    Chen YF; Yang Y; Hung HM; Wang SJ
    Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classifying responders and non-responders; does it help when there is evidence of differentially responding patient groups?
    Boessen R; Groenwold RH; Knol MJ; Grobbee DE; Roes KC
    J Psychiatr Res; 2012 Sep; 46(9):1169-73. PubMed ID: 22658815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine-lithium interaction.
    Gruwez B; Poirier MF; Dauphin A; Olié JP; Tod M
    Contemp Clin Trials; 2007 May; 28(3):276-87. PubMed ID: 17059901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.